SEC Tracker
Get the app

OnKure Therapeutics OKUR

OnKure Therapeutics reported a $17.85 million net loss

Form
10-Q
Filed
Importance
Notable
  1. Net loss of $17.85 million for the three months ended Sep 30, 2026
  2. Diluted EPS of -$0.36 for the three months ended Sep 30, 2026
  3. Cash and equivalents of $151.44 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when OnKure Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026

  • For the quarter ended September 30, 2026, OnKure Therapeutics, Inc. reported: Net income -$17.8 million.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Champions Oncology CSBR public float $29M, Oct 31, 2025
  2. Rockwell Medical RMTI public float $29M, Jun 30, 2025
  3. Outlook Therapeutics OTLK public float $27M, Mar 31, 2025, over 18 months old
  4. Cumberland Pharmaceuticals CPIX public float $29M, Jun 30, 2025
  5. ProMIS Neurosciences PMN public float $30M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.